Luxturna is a gene therapy.
The generic name of Luxturna is “voretigene neparvovec-rzyl”
Luxturna is a treatment for people who have Leber congenital amaurosis (LCA) or retinitis pigmentosa (RP) caused by mutations in both copies of the RPE65 gene. Luxturna provides a working copy of the RPE65 gene to restore the visual cycle. This allows photoreceptor cells in the retina to sense light and send a message to the brain. Evidence from clinical trials shows that this treatment can safely improve vision, particularly night vision and the ability to function independently.
Luxturna is a one-time treatment that can improve sight (especially night vision) and the ability to function independently.
LCA and RP are progressive eye diseases and EVERY DAY that individuals with these diseases wait for treatment, they are losing over 10,000 photoreceptors.
Time = Sight!
Here are news reports on Luxturna coming to Canada:
Anthonee’s story – CTV News Saskatoon
Nathan and Andre’s story – CTV News Toronto
William’s story – Global News Montreal
Nora’s Story – CTV News Atlantic
Fighting Blindness Canada, our vision partners, and the vision loss community have been actively advocating for access to Luxturna, and clear a path forward for future treatments to be publicly funded. Your help is needed now.
When research delivers treatments to transform lives, Canadians need timely access to these innovative treatments.